Abstract
Nonphysiologic overexpression of amyloid-beta (A beta) precursor protein in common transgenic A beta mouse models of Alzheimer disease likely hampers their translational potential. The novel App(NL-G-F) mouse incorporates a mutated knock-in, potentially presenting an improved model of Alzheimer disease for A beta-targeting treatment trials. We aimed to establish serial small-animal PET of amyloidosis and neuroinflammation in App(NL-G-F) mice as a tool for therapy monitoring. Methods: App(NL-G-F) mice (20 homozygous and 21 heterogeneous) and 12 age-matched wild-type mice were investigated longitudinally from 2.5 to 10 mo of age with F-18-florbetaben A beta PET and F-18-GE-180 18-kDa translocator protein (TSPO) PET. Voxelwise analysis of SUV ratio images was performed using statistical parametric mapping. All mice underwent a Morris water maze test of spatial learning after their final scan. Quantification of fibrillar A beta and activated microglia by immunohistochemistry and biochemistry served for validation of the PET results. Results: The periaqueductal gray emerged as a suitable pseudo reference tissue for both tracers. Homozygous App(NL-G-F) mice had a rising SUV ratio in cortex and hippocampus for A beta (+9.1%, +3.8%) and TSPO (+19.8%, +14.2%) PET from 2.5 to 10 mo of age (all P < 0.05), whereas heterozygous App(NL-G-F) mice did not show significant changes with age. Significant voxelwise clusters of A beta deposition and microglial activation in homozygous mice appeared at 5 mo of age. Immunohistochemical and biochemical findings correlated strongly with the PET data. Water maze escape latency was significantly elevated in homozygous App(NL-G-F) mice compared with wild-type at 10 mo of age and was associated with high TSPO binding. Conclusion: Longitudinal PET in App(NL-G-F) knock-in mice enables monitoring of amyloidogenesis and neuroinflammation in homozygous mice but is insensitive to minor changes in heterozygous animals. The combination of PET with behavioral tasks in App(NL-G-F) treatment trials is poised to provide important insights in preclinical drug development.
Dokumententyp: | Zeitschriftenartikel |
---|---|
Fakultät: | Medizin
Medizin > Munich Cluster for Systems Neurology (SyNergy) |
Themengebiete: | 600 Technik, Medizin, angewandte Wissenschaften > 610 Medizin und Gesundheit |
URN: | urn:nbn:de:bvb:19-epub-78541-1 |
ISSN: | 0161-5505 |
Sprache: | Englisch |
Dokumenten ID: | 78541 |
Datum der Veröffentlichung auf Open Access LMU: | 15. Dez. 2021, 14:44 |
Letzte Änderungen: | 02. Aug. 2024, 12:28 |
DFG: | Gefördert durch die Deutsche Forschungsgemeinschaft (DFG) - 390857198 |